BOTHELL, Wash., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, presented results from its Phase 1 clinical trial of ATH-1105 in healthy volunteers at the ALS Nexus 2025 conference in Dallas, Texas. ALS Nexus convenes leading experts from the ALS community, including researchers, healthcare professionals, advocates and individuals living with amyotrophic lateral sclerosis (ALS), to connect and learn about advances in research, clinical care and advocacy.
Related Questions
Are there any safety signals or adverse events that could delay or halt further development?
What is the timeline for moving into Phase 2/3 trials, and how does that compare to the company's previous milestones?
How does ATH-1105's mechanism of action compare to existing ALS therapeutics and pipeline candidates from competitors?
What is the expected market size for an ALS therapy and how might ATH-1105 capture share if successful?
Did the company disclose any updates on funding requirements or potential dilution from upcoming financing rounds?
Will the Phase 1 data trigger any partnership or licensing discussions with larger pharmaceutical firms?
How might the results influence analyst rating upgrades/downgrades or target price revisions for ATHA?
How will the Phase 1 results of ATH-1105 affect Athira Pharma's stock price in the short term?
What specific efficacy and safety data were reported, and do they meet or exceed investor expectations?
What impact could this news have on the broader neurodegeneration sector and related biotech stocks?